Silver Book Fact

Valuing a QALY at $175,000, new drugs that would produce a 5-year delay in Alzheimer’s disease onset for all new cases between 2010 and 2050 would yield a benefit of close to $4 trillion per year.

Vernon J, Goldberg R, Dash Y, Muralimohan G. Alzheimer’s Disease and Cost-effectiveness Analyses: Ensuring good value for money?. Working Paper — Pending Publication; 2007. http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=12477

Reference

Title
Alzheimer’s Disease and Cost-effectiveness Analyses: Ensuring good value for money?
Publisher
Working Paper — Pending Publication
Publication Date
2007
Authors
Vernon J, Goldberg R, Dash Y, Muralimohan G
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • An Alzheimer’s treatment breakthrough that slowed progression and began to show its effects in 2015, would reduce out-of-pocket costs to people with the disease by $8 billion in 2020–from the…  
  • It is imperative to weigh costs of implementing new technologies for predicting onset of Alzheimer’s disease through biomarkers and delaying onset earlier against the potential benefits of improving health. Overall…  
  • 32 drugs are currently in development for Parkinson’s disease.  
  • An Alzheimer’s disease treatment breakthrough that slowed its progression and began to show its effects in 2015, would reduce the Medicare costs for people with the disease by $20 billion…  
  • A clinical trial in Europe found that treating Alzheimer’s patients with an Alzheimer’s drug reduced annual treatment costs by $1,000 per patient.